ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 1965 • ACR Convergence 2023

    Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study

    Mrinalini Dey1, Rudra Prosad Goswami2, Parikshit Sen3, Samuel Shinjo4, Nelly Ziade5, Ioannis Parodis6, Mrudula Joshi7, Marcin Milchert8, Abraham Edgar Gracia-Ramos9, Lorenzo Cavagna10, Vishwesh Agarwal11, Johannes Knitza12, Jessica Day13, Hector Chinoy14, COVAD Study Group15, Vikas Agarwal16, Rohit Aggarwal17 and Latika Gupta18, 1Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, 2Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India, 3Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, 4Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, 5Saint-Joseph University, Beirut, Lebanon, 6Karolinska Institutet, Stockholm, Sweden, 7Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, 8Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, 9Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, 10Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 11Mahatma Gandhi Missions Medical College, Lucknow, India, 12Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, 13Walter and Eliza Hall Institute, Melbourne, Australia, 14The University of Manchester, Sale, United Kingdom, 15-, -, 16Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 17University of Pittsburgh, Pittsburgh, PA, 18Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom

    Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…
  • Abstract Number: 2579 • ACR Convergence 2023

    Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies

    Emma Austenfeld1, Sara Sabbagh1, Melodee Liegl1, Ke Yan1, Julie Fuller2, Kelly Rouster-Stevens3, Lisa Rider4 and Adam Schiffenbauer4, 1Medical College of Wisconsin, Wauwatosa, WI, 2UT Southwestern and Scottish Rite for Children, Dallas, TX, 3Emory University/Children's Healthcare of Atlanta, Norcross, GA, 4NIEHS, NIH, Bethesda, MD

    Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
  • Abstract Number: 0288 • ACR Convergence 2023

    Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)

    Sangmee Bae1, Ani Shahbazian1, Jennifer Wang2, Dawoud Sulaiman3, David Meriwether4, srinivasa Reddy5 and Christina Charles-Schoeman6, 1UCLA Rheumatology, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3UCLA Cardiology, Los Angeles, CA, 4UCLA Digestive Diseases, Los Angeles, CA, 5UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, 6UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Lipid oxidation products produced by artery wall cells under oxidative stress not only regulate immune responses, but their accumulation in HDL are shown to…
  • Abstract Number: 0748 • ACR Convergence 2023

    Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT

    Kastriot Kastrati1, Thomas S Nakuz2, Oana C Kulterer2, Stephan Blüml3, Michael Bonelli3, Irina Gessl4, Hans-Peter Kiener3, Werner Langsteger2, Daniel Mrak3, Florian Prayer5, Helmut Prosch5, Elisabeth Simader3, Tatjana Traub-Weidinger2, Daniel Aletaha6, Helga Radner7, Marcus Hacker2 and Peter Mandl3, 1Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, 2Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 4Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 5Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, 7Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
  • Abstract Number: 1170 • ACR Convergence 2023

    Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life

    Chiara Cardelli1, Simone Barsotti2, Elenia Laurino1, Michele Diomedi1, Federico Fattorini1, Alessandra Tripoli1, Linda Carli1 and Marta Mosca1, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Internal Medicine, Ospedale di Livorno, Pisa, Italy

    Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
  • Abstract Number: 1945 • ACR Convergence 2023

    Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals

    Arturo Llobell1, Inigo Gonzalez-Mazon2, carmen secada3, Adrian Martin-Gutierrez3, Almudena García-Castaño3, Enrique Gallardo4, Soledad Retamozo5, Antonio Gomez-Centeno6, Luis Fernandez-Morales4, Jordi Gratacos Masmitja7 and Ricardo Blanco8, 1Parc Tauli University Hospital, Barcelona, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Parc Taulí University Hospital, Sabadell, Spain, 5Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, 6Parc Taulí Hospital Universitari, Sabadell, Spain, 7University Hospital Parc Taulí, Sabadell, Spain, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
  • Abstract Number: 1967 • ACR Convergence 2023

    Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment

    Ana Valle1, Talia Meisel1, Xianhong Xie2 and Shereen Mahmood3, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY

    Background/Purpose: Over the last few decades, it has been established that multiple infections can mimic idiopathic inflammatory myopathies (IIM). HIV, HTLV-1, and Lyme disease are…
  • Abstract Number: 0291 • ACR Convergence 2023

    Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics

    Shun Nomura, Yasuhiro Shimojima, Takanori Ichikawa, Daigo Miyazaki, Dai Kishida and Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…
  • Abstract Number: 0783 • ACR Convergence 2023

    Tolerability of CAR T Cell Therapy in Autoimmune Disease

    Jule Taubmann1, Fabian Müller2, Michael Aigner3, Ioanna Minopoulou4, Johannes Knitza5, Dagmar Werner6, Christina Bergmann7, Gerhard Kroenke8, Andreas Mackensen3 and Georg Schett6, 1Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, 2Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, 4Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 5Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, 6FAU Erlangen-Nürnberg, Erlangen, Germany, 7Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 8Charite Berlin, Berlin, Germany

    Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
  • Abstract Number: 1171 • ACR Convergence 2023

    Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies

    Caoilfhionn M. Connolly1, Jana Lovell2, Melody Chung3, Brittany Adler2, Jemima Albayda2, Eleni Tiniakou2, Christopher Mecoli1, Stefan Zimmerman2, Lisa Christopher-Stine2, Nisha Gilotra2 and Julie Paik2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Kaiser Permanante, Baltimore, MD

    Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its associated morbidity and mortality. As manifestations of myocarditis can be mild or subclinical…
  • Abstract Number: 1946 • ACR Convergence 2023

    Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis

    Rohit Aggarwal1, Namita Goyal2, Diana Lam3, Allen Ng3, Richard Leff4, Kathryn Ray3, Eunmi Park3 and Noreen Henig3, 1University of Pittsburgh, Pittsburgh, PA, 2UCI Health, Orange, CA, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Chadds Ford, PA

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. In a collagen-induced myositis mouse model, immunoproteasome inhibition has…
  • Abstract Number: 1968 • ACR Convergence 2023

    Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population

    Ana Valle1, Melissa Fazzari2 and Shereen Mahmood3, 1Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune conditions which cause multi-organ inflammation, particularly in the skin, lungs, and muscles. It is known that many…
  • Abstract Number: 0292 • ACR Convergence 2023

    Comparison of Cardiovascular Risk of Myositis Patients and the General Population

    Sabina Oreska1, Hana Storkanova1, Jaroslav Kudlicka2, Vladimir Tuka2, Ondrej Mikes2, Zdislava Krupickova2, Martin Satny2, Eva Chytilova2, Jan Kvasnicka2, Maja Spiritovic3, Barbora Hermankova4, Petr Cesak5, Marian Rybar6, Karel Pavelka1, Ladislav Senolt7, Herman Mann8, Jiri Vencovsky1, Michal Vrablik2 and Michal Tomcik1, 1Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 23rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, 4Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, 5Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, 6Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, 7Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, 8Institute of Rheumatology, Praha 2, Czech Republic

    Background/Purpose: Cardiovascular (CV) risk due to accelerated atherosclerosis and impaired metabolism can be increased in idiopathic inflammatory myopathies (IIM) on behalf of systemic inflammation, limited…
  • Abstract Number: 1022 • ACR Convergence 2023

    Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)

    Joseph Fares1, ross Summer1 and Giorgos Loizidis2, 1The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, 2Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA

    Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
  • Abstract Number: 1173 • ACR Convergence 2023

    Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease

    Toshimasa Shimizu1, Haruna Matsuo2, Tomohiro Koga3, Noriho Sakamoto4, Hiroshi Mukae1 and Atsushi Kawakami1, 1Nagasaki University, Nagasaki, Japan, 2Nagasaki University, Nagasaki City, Japan, 3Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, 4Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a chronic inflammatory disorder involved in skeletal muscles. Interstitial lung disease (ILD) as an organ lesion is a common…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology